Search

Your search keyword '"Dreger, Peter"' showing total 1,374 results
Start Over Author "Dreger, Peter" Publication Year Range Last 10 years
1,374 results on '"Dreger, Peter"'

51. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Author

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes, Fürstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Dürig, Jan, Böttcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Döhner, Hartmut, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan

Published
2022
Full Text
View/download PDF

52. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

Author

Hamadani, Mehdi, Ngoya, Maud, Sureda, Anna, Bashir, Qaiser, Litovich, Carlos Alejandro, Finel, Hervé, Chen, Yue, Boumendil, Ariane, Zain, Jasmine, Castagna, Luca, Cashen, Amanda F., Blaise, Didier, Shadman, Mazyar, Pastano, Rocco, Khimani, Farhad, Arat, Mutlu, Dietrich, Sascha, Schmitz, Norbert, Glass, Bertram, Kharfan-Dabaja, Mohamed A., Corradini, Paolo, Sauter, Craig S., Montoto, Silvia, Kwon, Mi, Herrera, Alex F., and Dreger, Peter

Published
2022
Full Text
View/download PDF

53. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

54. Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years.

Author

Berning, Philipp, Fekom, Mathilde, Ngoya, Maud, Goldstone, Anthony H., Dreger, Peter, Montoto, Silvia, Finel, Hervé, Shumilov, Evgenii, Chevallier, Patrice, Blaise, Didier, Strüssmann, Tim, Carpenter, Ben, Forcade, Edouard, Castilla-Llorente, Cristina, Trneny, Marek, Ghesquieres, Hervé, Capria, Saveria, Thieblemont, Catherine, Blau, Igor Wolfgang, and Meijer, Ellen

Subjects
HEMATOPOIETIC stem cell transplantation, DIFFUSE large B-cell lymphomas, BONE marrow
Abstract

Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990–1994) to 58 years (2015–2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased from 36 (1990–1994) to 54 (2015–2021) years, with mobilized blood as the primary source post-1998 and reduced intensity conditioning post-2000. Unrelated and mismatched allo-HSCT accounted for 50% and 19% of allo-HSCT in 2015–2021. Three-year overall survival (OS) after auto-HSCT improved from 56% (1990–1994) to 70% (2015–2021), p < 0.001, with a decrease in relapse incidence (RI) from 49% to 38%, while non-relapse mortality (NRM) remained unchanged (4%). After allo-HSCT, 3-year-OS increased from 33% (1990–1999) to 46% (2015–2021) (p < 0.001); 3-year RI remained at 39% and 1-year-NRM decreased to 19% (p < 0.001). Our data reflect advancements over 32 years and >40,000 transplants, providing insights for evaluating emerging DLBCL therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

55. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.

Author

Kilian, Michael, Friedrich, Mirco J., Lu, Kevin Hai-Ning, Vonhören, David, Jansky, Selina, Michel, Julius, Keib, Anna, Stange, Saskia, Hackert, Nicolaj, Kehl, Niklas, Hahn, Markus, Habel, Antje, Jung, Stefanie, Jähne, Kristine, Sahm, Felix, Betge, Johannes, Cerwenka, Adelheid, Westermann, Frank, Dreger, Peter, and Raab, Marc S.

Subjects
KILLER cells, T cells, AUTOIMMUNE diseases, CELL adhesion molecules, T cell receptors, CELLULAR recognition, IMMUNE checkpoint inhibitors, CANCER cells
Abstract

Understanding the mechanisms that regulate T cell immunity is critical for the development of effective therapies for diseases associated with T cell dysfunction, including autoimmune diseases, chronic infections, and cancer. Co-inhibitory "checkpoint molecules," such as programmed cell death protein-1, balance excessive or prolonged immune activation by T cell–intrinsic signaling. Here, by screening for mediators of natural killer (NK) cell recognition on T cells, we identified the immunoglobulin superfamily ligand B7H6 to be highly expressed by activated T cells, including patient-infused CD19-targeting chimeric antigen receptor (CAR) T cells. Unlike other checkpoint molecules, B7H6 mediated NKp30-dependent recognition and subsequent cytolysis of activated T cells by NK cells. B7H6+ T cells were prevalent in the tissue and blood of several diseases, and their abundance in tumor tissue positively correlated with clinical response in a cohort of patients with immune checkpoint inhibitor–treated esophageal cancer. In humanized mouse models, NK cell surveillance via B7H6 limited the persistence and antitumor activity of CAR T cells, and its genetic deletion enhanced T cell proliferation and persistence. Together, we provide evidence of B7H6 protein expression by activated T cells and suggest the B7H6-NKp30 axis as a therapeutically actionable NK cell–dependent immune checkpoint that regulates human T cell function. Editor's summary: Natural killer (NK) cells can eliminate infected or malignant cells, but they are also believed to be capable of killing host immune cells. By screening NK cell ligands on human T cells, Kilian et al. found that the immunoglobulin superfamily ligand B7H6 promotes cytolysis of activated T cells by NK cells. In leukemia-bearing humanized mice, NK cells restricted the antitumor activity of chimeric antigen receptor (CAR) T cells in a B7H6-dependent manner. A higher ratio of intratumoral NK to T cells was associated with poor response to immune checkpoint inhibition in a cohort of patients with esophageal cancer. These findings demonstrate that B7H6 recognition by NK cells can restrict human antitumor T cell responses. —Claire Olingy [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

56. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients.

Author

Schmälter, Ann-Kristin, Ngoya, Maud, Galimard, Jacques-Emmanuel, Bazarbachi, Ali, Finke, Jürgen, Kröger, Nicolaus, Bornhäuser, Martin, Stelljes, Matthias, Stölzel, Friedrich, Tischer, Johanna, Schroeder, Thomas, Dreger, Peter, Blau, Igor-Wolfgang, Savani, Bipin, Giebel, Sebastian, Esteve, Jordi, Nagler, Arnon, Schmid, Christoph, Ciceri, Fabio, and Mohty, Mohamad

Subjects
STEM cell transplantation, ACUTE myeloid leukemia, GRAFT versus host disease
Abstract

Second allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome. Among 1540 recipients of alloSCT2, increasing age, better disease control and performance status before alloSCT2, more use of alternative donors and higher conditioning intensity represented important trends over time. Between the first (2000–2004) and last (2015–2019) period, two-year overall and leukemia-free survival (OS/LFS) increased considerably (OS: 22.5–35%, LFS: 14.5–24.5%). Cumulative relapse incidence (RI) decreased from 64% to 50.7%, whereas graft-versus-host disease and non-relapse mortality (NRM) remained unchanged. In multivariable analysis, later period of alloSCT2 was associated with improved OS/LFS (HR = 0.47/0.53) and reduced RI (HR = 0.44). Beyond, remission duration, disease stage and patient performance score were factors for OS, LFS, RI, and NRM. Myeloablative conditioning for alloSCT2 decreased RI without increasing NRM, leading to improved OS/LFS. Haploidentical or unrelated donors and older age were associated with higher NRM and inferior OS. In summary, outcome after alloSCT2 has continuously improved over the last two decades despite increasing patient age. The identified factors provide clues for the optimized implementation of alloSCT2. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

57. Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study

Author

Martino, Massimo, Pitino, Annalisa, Gori, Mercedes, Viens, Patrice, Siena, Salvatore, Tripepi, Giovanni, Canale, Filippo Antonio, Ballestrero, Alberto, Zamagni, Claudio, Musso, Maurizio, Zambelli, Alberto, Dreger, Peter, Badoglio, Manuela, Secondino, Simona, Console, Giuseppe, Chabannon, Christian, and Pedrazzoli, Paolo

Published
2022
Full Text
View/download PDF

62. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study

Author

Penack, Olaf, primary, Luft, Thomas, additional, Peczynski, Christophe, additional, Benner, Axel, additional, Sica, Simona, additional, Arat, Mutlu, additional, Itäla-Remes, Maija, additional, Corral, Lucia López, additional, Schaap, Nicolaas P M, additional, Karas, Michal, additional, Raida, Ludek, additional, Schroeder, Thomas, additional, Dreger, Peter, additional, Metafuni, Elisabetta, additional, Ozcelik, Tulay, additional, Sandmaier, Brenda M, additional, Kordelas, Lambros, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Koenecke, Christian, additional, Basak, Grzegorz W, additional, and Peric, Zinaida, additional

Published
2024
Full Text
View/download PDF

65. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

66. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis

Author

Merkt, Wolfgang, primary, Freitag, Merle, additional, Claus, Maren, additional, Kolb, Philipp, additional, Falcone, Valeria, additional, Röhrich, Manuel, additional, Rodon, Lea, additional, Deicher, Franca, additional, Andreeva, Ivana, additional, Tretter, Theresa, additional, Tykocinski, Lars-Oliver, additional, Blank, Norbert, additional, Watzl, Carsten, additional, Schmitt, Anita, additional, Sauer, Tim, additional, Müller-Tidow, Carsten, additional, Polke, Markus, additional, Heußel, Claus Peter, additional, Dreger, Peter, additional, Lorenz, Hanns-Martin, additional, and Schmitt, Michael, additional

Published
2023
Full Text
View/download PDF

68. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation

Author

Spyridonidis, Alexandros, primary, Labopin, Myriam, additional, Gedde-Dahl, Tobias, additional, Ganser, Arnold, additional, Stelljes, Matthias, additional, Craddock, Charles, additional, Wagner-Drouet, Eva Maria, additional, Versluis, Jurjen, additional, Schroeder, Thomas, additional, Blau, Igor Wolfgang, additional, Wulf, Gerald. G., additional, Dreger, Peter, additional, Olesen, Gitte, additional, Sengeloev, Henrik, additional, Kröger, Nicolaus, additional, Potter, Victoria, additional, Forcade, Edouard, additional, Passweg, Jakob, additional, de Latour, Régis Peffault, additional, Maertens, Johan, additional, Wilson, Keith M. O., additional, Bourhis, Jean Henri, additional, Finke, Juergen, additional, Brissot, Eolia, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Savani, Bipin P., additional, Nagler, Arnon, additional, Ciceri, Fabio, additional, and Mohty, Mohamad, additional

Published
2023
Full Text
View/download PDF

70. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Author

Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva, Acker, Fabian, Fuhrmann, Stephan, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caillé, Léandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter, and Dietrich, Sascha

Published
2021
Full Text
View/download PDF

72. Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Author

Nagler, Arnon, Peczynski, Christophe, Dholaria, Bhagirathbhai, Labopin, Myriam, Valerius, Thomas, Dreger, Peter, Kröger, Nicolaus, Reinhardt, Hans Christian, Finke, Jürgen, Franke, Georg-Nikolaus, Ciceri, Fabio, Verbeek, Mareike, Blau, Igor Wolfgang, Bornhäuser, Martin, Spyridonidis, Alexandros, Bug, Gesine, Bazarbachi, Ali, Schmid, Christophe, Yakoub-Agha, Ibrahim, Savani, Bipin N., and Mohty, Mohamad

Published
2022
Full Text
View/download PDF

73. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, Chevallier, Patrice, van Gelder, Michel, Hoek, Jennifer, Hermine, Olivier, Chakraverty, Ronjon, Browne, Paul, Milpied, Noel, Malagola, Michele, Socié, Gerard, Delgado, Julio, Deconinck, Eric, Damaj, Ghandi, Maury, Sebastian, Beelen, Dietrich, Quoc, Stéphanie Nguyen, Shankara, Paneesha, Brecht, Arne, Mayer, Jiri, Hunault-Berger, Mathilde, Bittenbring, Jörg, Thieblemont, Catherine, Lepretre, Stéphane, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, and Dreger, Peter

Published
2021
Full Text
View/download PDF

74. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Author

Schetelig, Johannes, Hoek, Jennifer, Stilgenbauer, Stephan, Middeke, Jan Moritz, Andersen, Niels Smedegaard, Fox, Christopher P., Lenhoff, Stig, Volin, Liisa, Shimoni, Avichai, Schroyens, Wilfried, van Gelder, Michel, Bunjes, Donald, van Biezen, Anja, Baldauf, Henning, de Wreede, Liesbeth C., Tournilhac, Olivier, Kröger, Nicolaus, Yakoub-Agha, Ibrahim, and Dreger, Peter

Published
2021
Full Text
View/download PDF

75. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A, Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P, Awan, Farrukh T, Ayala, Ernesto, Barrientos, Jacqueline C, Brown, Jennifer R, Castro, Januario E, Furman, Richard R, Gribben, John, Hill, Brian T, Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z, Pinilla-Ibarz, Javier, Reddy, Nishitha M, Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Transplantation, Hematology, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Lymphoma, Antineoplastic Agents, Child, Child, Preschool, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Practice Guidelines as Topic, Salvage Therapy, Transplantation Conditioning, Transplantation, Homologous, Chronic lymphocytic leukemia, Allogeneic hematopoietic cell transplantation, BCR inhibitors, BCL-2 inhibitors, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.

Published
2016

76. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison

Author

Dreger, Peter, Dietrich, Sascha, Schubert, Maria-Luisa, Selberg, Lorenz, Bondong, Andrea, Wegner, Mandy, Stadtherr, Peter, Kimmich, Christoph, Kosely, Florentina, Schmitt, Anita, Pavel, Petra, Liebers, Nora, Luft, Thomas, Hegenbart, Ute, Radujkovic, Aleksandar, Ho, Anthony Dick, Müller-Tidow, Carsten, and Schmitt, Michael

Published
2020
Full Text
View/download PDF

78. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Author

Roeker, Lindsey E., Dreger, Peter, Brown, Jennifer R., Lahoud, Oscar B., Eyre, Toby A., Brander, Danielle M., Skarbnik, Alan, Coombs, Catherine C., Kim, Haesook T., Davids, Matthew, Manchini, Steven T., George, Gemlyn, Shah, Nirav, Voorhees, Timothy J., Orchard, Kim H., Walter, Harriet S., Arumainathan, Arvind K., Sitlinger, Andrea, Park, Jae H., Geyer, Mark B., Zelenetz, Andrew D., Sauter, Craig S., Giralt, Sergio A., Perales, Miguel-Angel, and Mato, Anthony R.

Published
2020
Full Text
View/download PDF

80. Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Author

Hernández-Boluda, Juan Carlos, Pereira, Arturo, Kröger, Nicolaus, Beelen, Dietrich, Robin, Marie, Bornhäuser, Martin, Angelucci, Emanuele, Vitek, Antonin, Blau, Igor Wolfgang, Niittyvuopio, Riitta, Finke, Jürgen, Cornelissen, Jan J., Passweg, Jakob, Dreger, Peter, Petersen, Eefke, Kanz, Lothar, Sanz, Jaime, Zuckerman, Tsila, Zinger, Nienke, Iacobelli, Simona, Hayden, Patrick, Czerw, Tomasz, McLornan, Donal, and Yakoub-Agha, Ibrahim

Published
2021
Full Text
View/download PDF

83. Management of Patients Undergoing CAR-T Cell Therapy in Germany.

Author

Penack, Olaf, Dreger, Peter, Ajib, Salem, Ayuk, Francis, Baermann, Ben-Niklas, Bug, Gesine, Kriege, Oliver, Jentzsch, Madlen, Kobbe, Guido, Koenecke, Christian, Lutz, Mathias, Martin, Sonja, Schlegel, Paul-Gerhard, Schroers, Roland, von Tresckow, Bastian, Vucinic, Vladan, Subklewe, Marion, Bethge, Wolfgang, and Wolff, Daniel

Subjects
*STEM cell transplantation, *CELLULAR therapy, *HEMATOPOIETIC stem cell transplantation, *CELL transplantation, *CYTOKINE release syndrome, *NON-Hodgkin's lymphoma
Abstract

Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin's lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no – or low quality – clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

87. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Author

Beelen, Dietrich Wilhelm, Trenschel, Rudolf, Stelljes, Matthias, Groth, Christoph, Masszi, Tamás, Reményi, Péter, Wagner-Drouet, Eva-Maria, Hauptrock, Beate, Dreger, Peter, Luft, Thomas, Bethge, Wolfgang, Vogel, Wichard, Ciceri, Fabio, Peccatori, Jacopo, Stölzel, Friedrich, Schetelig, Johannes, Junghanß, Christian, Grosse-Thie, Christina, Michallet, Mauricette, Labussiere-Wallet, Hélène, Schaefer-Eckart, Kerstin, Dressler, Sabine, Grigoleit, Goetz Ulrich, Mielke, Stephan, Scheid, Christof, Holtick, Udo, Patriarca, Francesca, Medeot, Marta, Rambaldi, Alessandro, Micò, Maria Caterina, Niederwieser, Dietger, Franke, Georg-Nikolaus, Hilgendorf, Inken, Winkelmann, Nils Rudolf, Russo, Domenico, Socié, Gérard, Peffault de Latour, Régis, Holler, Ernst, Wolff, Daniel, Glass, Bertram, Casper, Jochen, Wulf, Gerald, Menzel, Helge, Basara, Nadezda, Bieniaszewska, Maria, Stuhler, Gernot, Verbeek, Mareike, Grass, Sandra, Iori, Anna Paola, Finke, Juergen, Benedetti, Fabio, Pichlmeier, Uwe, Hemmelmann, Claudia, Tribanek, Michael, Klein, Anja, Mylius, Heidrun Anke, Baumgart, Joachim, Dzierzak-Mietla, Monika, and Markiewicz, Miroslaw

Published
2020
Full Text
View/download PDF

88. Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation

Author

Heilig, Christoph E., Badoglio, Manuela, Labopin, Myriam, Fröhling, Stefan, Secondino, Simona, Heinz, Jürgen, Nicolas-Virelizier, Emmanuelle, Blaise, Didier, Korenbaum, Clément, Santoro, Armando, Verbeek, Mareike, Krüger, William, Siena, Salvatore, Passweg, Jakob R., Di Nicola, Massimo, Rifón, Jose, Dreger, Peter, Koehl, Ulrike, Chabannon, Christian, and Pedrazzoli, Paolo

Published
2020
Full Text
View/download PDF

89. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Author

Schubert, Maria-Luisa, primary, Bethge, Wolfgang A., additional, Ayuk, Francis A., additional, von Bonin, Malte, additional, Vucinic, Vladan, additional, Wagner-Drouet, Eva Marie, additional, Subklewe, Marion, additional, Baldus, Claudia D., additional, Glass, Bertram, additional, Marks, Reinhard, additional, Mougiakakos, Dimitrios, additional, Schroers, Roland, additional, Stelljes, Matthias, additional, Topp, Max S., additional, Wulf, Gerald, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2023
Full Text
View/download PDF

91. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

Author

Penack, Olaf, primary, Peczynski, Christophe, additional, Koenecke, Christian, additional, Polge, Emmanuelle, additional, Sanderson, Robin, additional, Yakoub-Agha, Ibrahim, additional, Fegueux, Nathalie, additional, Daskalakis, Michael, additional, Collin, Matthew, additional, Dreger, Peter, additional, Kröger, Nicolaus, additional, Schanz, Urs, additional, Bloor, Adrian, additional, Ganser, Arnold, additional, Besley, Caroline, additional, Wulf, Gerald G., additional, Novak, Urban, additional, Moiseev, Ivan, additional, Schoemans, Hélène, additional, Basak, Grzegorz W., additional, Chabannon, Christian, additional, Sureda, Anna, additional, Glass, Bertram, additional, and Peric, Zinaida, additional

Published
2023
Full Text
View/download PDF

93. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

Author

Weller, Jan Frederic, primary, Lengerke, Claudia, additional, Finke, Jürgen, additional, Schetelig, Johannes, additional, Platzbecker, Uwe, additional, Einsele, Hermann, additional, Schroeder, Thomas, additional, Faul, Christoph, additional, Stelljes, Matthias, additional, Dreger, Peter, additional, Blau, Igor W., additional, Wulf, Gerald, additional, Tischer, Johanna, additional, Scheid, Christoph, additional, Elmaagacli, Ahmet, additional, Neidlinger, Helga, additional, Flossdorf, Sarah, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang, additional, Fleischhauer, Katharina, additional, Kröger, Nicolaus, additional, De Wreede, Liesbeth C., additional, and Christopeit, Maximilian, additional

Published
2023
Full Text
View/download PDF

94. S225: ALLOGENEIC STEM CELL TRANSPLANTATION FOR NK/T-CELL LYMPHOMA IN THE ERA OF ASPARAGINASE-BASED CHEMOTHERAPY: A RETROSPECTIVE ANALYSIS OF THE EBMT LYMPHOMA WORKING PARTY

Author

Berning, Philipp, primary, Schmitz, Norbert, additional, Ngoya, Maud, additional, Finel, Hevé, additional, Boumendil, Ariane, additional, Wang, Fengrong, additional, Huang, Xiaojun, additional, Hermine, Olivier, additional, Philippe, Laure, additional, Couronné, Lucile, additional, Jaccard, Arnaud, additional, Liu, Dai-Hong, additional, Wu, Depei, additional, Reinhardt, Christian, additional, Chalandon, Yves, additional, Wagner-Drouet, Eva, additional, Kwon, MI, additional, Zhang, XI, additional, Carpenter, Ben, additional, Yakoub-Agha, Ibrahim, additional, Wulf, Gerald, additional, Jimenez, Francisco Lopez, additional, Sanz, Jaime, additional, Wallet, Hélène Labussiere, additional, Shimoni, Avichai, additional, Dreger, Peter, additional, Sureda, Anna, additional, Kim, Won-Seog, additional, and Glass, Bertram, additional

Published
2023
Full Text
View/download PDF

96. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

Author

Mussetti, Alberto, Kanate, Abraham S., Wang, Tao, He, Meilun, Hamadani, Mehdi, Finel, Hervé, Sr., Boumendil, Ariane, Sr., Glass, Bertram, Castagna, Luca, Dominietto, Alida, McGuirk, Joseph, Blaise, Didier, Gülbas, Zafer, Diez-Martin, Jose, Marsh, Steven G.E., Paczesny, Sophie, Gadalla, Shahinaz M., Dreger, Peter, Zhang, Mei-Jie, Spellman, Stephen R., Lee, Stephanie J., Bolon, Yung-Tsi, and Sureda, Anna

Published
2023
Full Text
View/download PDF

97. Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Author

Faraci, Maura, Diesch, Tamara, Labopin, Myriam, Dalissier, Arnaud, Lankester, Arian, Gennery, Andrew, Sundin, Mikael, Uckan-Cetinkaya, Duygu, Bierings, Marc, Peters, Anke M.J., Garwer, Martina, Schulz, Ansgar, Michel, Gerard, Giorgiani, Giovanna, Gruhn, Bernd, Locatelli, Franco, Giardino, Stefano, Uyttebroeck, Anne, Rialland, Fanny, Itäla-Remes, Maija, Dreger, Peter, Shaw, Peter J., Bordon, Victoria, Schlegel, Paul G., Mellgren, Karin, Moraleda, Jose M., Patrick, Katharine, Schneider, Pascale, Jubert, Charlotte, Lawitschka, Anita, Salooja, Nina, Basak, Grzegorz W., Corbacioglu, Selim, Duarte, Rafael, and Bader, Peter

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results